Ticker LaunchIPO · GLSI
Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (GLSI) priced its initial public offering on Sep 28, 2020 at $5.75 per share, raising $7.3M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $68.8M. Sheppard Mullin advised the company and Sichenzia Ross Ference Carmel advised the underwriters.
Greenwich LifeSciences, Inc. is a biopharmaceutical company developing GP2, an immunotherapy designed to prevent breast cancer recurrence after surgery. GP2 is a peptide of the HER2/neu protein, and the company plans to begin a Phase III trial in late 2020 or early 2021.
- Status
- IPO
- Ticker
- GLSI
- Exchange
- Nasdaq Capital Market
- Priced
- Sep 28, 2020
- IPO price
- $5.75
- Raised
- $7.3M
- Market cap at IPO price
- $68.8M
- First filed
- May 29, 2020
- Company counsel
- Sheppard Mullin
- Underwriters' counsel
- Sichenzia Ross Ference Carmel
- Sector
- Biotech & pharma
- Country / state
- TX
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 29, 2020
- Latest amendment Sep 10, 2020
- Final prospectus (424B4) Sep 28, 2020
- All filings on EDGAR CIK 1799788
Other Biotech & pharma IPOs in 2020
- C4 Therapeutics, Inc.CCCC · Oct 2, 2020 · $182.4M
- Orphazyme A/SORPH · Sep 29, 2020 · $83.8M
- CalciMedica, Inc.GRAY · Sep 25, 2020 · $90M
- PMV Pharmaceuticals, Inc.PMVP · Sep 25, 2020 · $211.8M
- Prelude Therapeutics IncPRLD · Sep 25, 2020 · $158.2M
- Taysha Gene Therapies, Inc.TSHA · Sep 25, 2020 · $157.4M